DLBCL Treatment in Children and Adolescents
Launched by SUN YAT-SEN UNIVERSITY · Jan 25, 2021
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that accounts for approximately 10%-20% of pediatric and adolescent non-Hodgkin's lymphomas (NHLs).
The incidence increases with age, with 37% of NHLs patients being adolescents aged. Poor survival has been demonstrated in adolescents and young adults compared to children with DLBCL. However, the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) LNH-97 study showed that age was not a poor prognostic factor in children and adolescents with Burkitt lymphoma (BL) and DLBCL. A conclusion as to whether adolescent age is...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. patients who were pathologically diagnosed with DLBCL
- • 2. patients under 18 years of age.
- Exclusion Criteria:
- • 1. Was administered prior chemotherapy;
- • 2. Patients who could not receive chemotherapy due to severe immunodeficiency or other diseases.
- • 3. Patients with primary central nervous system lymphomas.
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yizhuo Zhang
Principal Investigator
Sun Yat-sen University CancerCenter
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials